Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + HRS-7058
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Adebrelimab + HRS-7058 is an investigational combination therapy being developed by Jiangsu Hengrui Pharmaceuticals (through its subsidiary Suzhou Suncadia Biopharmaceuticals) for the treatment of non-small cell lung cancer (NSCLC). Adebrelimab is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to restore T-cell mediated anti-tumor activity. HRS-7058 is an investigational small molecule inhibitor of Son of Sevenless homolog 1 (SOS1), a guanine nucleotide exchange factor that plays a critical role in the activation of RAS proteins. By inhibiting SOS1, HRS-7058 aims to disrupt the MAPK signaling pathway, which is frequently dysregulated in various cancers. The combination is currently being evaluated in Phase II clinical trials as a perioperative treatment for patients with resectable NSCLC, leveraging both immune checkpoint blockade and targeted inhibition of oncogenic signaling.
- Other names
- adebelizumab + HRS-7058
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on adebrelimab + HRS-7058.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + HRS-7058.